ACP
IBB icon

Aviance Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Aviance Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,300
Closed -$210K – 258
2021
Q3 		$210K Hold
1,300
– – 0.04% 243
2021
Q2 		$213K Buy
+1,300
New +$200K 0.04% 242

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Aviance Capital Partners's IBB Position: Q4 2021 in Review

Aviance Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q4 2021, closing a stake of 1,300 shares — an estimated $210K sold.

Aviance Capital Partners first reported a position in IBB in Q2 2021 and held it in 2 quarters. The position peaked at $213K in Q2 2021. 962 funds tracked by Wall St. Rank hold IBB as of Q4 2021.

  • Aviance Capital Partners reported no remaining iShares Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
  • Aviance Capital Partners sold 1,300 iShares Biotechnology ETF shares in Q4 2021, an estimated $210K.
  • Aviance Capital Partners first reported a position in iShares Biotechnology ETF in Q2 2021 and held it in 2 quarters.
  • Aviance Capital Partners's iShares Biotechnology ETF position peaked at $213K in Q2 2021.
  • 962 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2021.

Based on Aviance Capital Partners's 13F filing for Q4 2021, filed 7 Feb 2022.